Ozempic vs Wegovy: They're the Same Drug — Here's What Actually Differs

The core fact: same molecule, different approvals

Ozempic and Wegovy are both manufactured by Novo Nordisk and both contain semaglutide — the same active ingredient. You could describe them as two brand names for the same drug at different doses.

The specific differences:

Why two brand names exist for the same molecule

Pharmaceutical regulatory strategy: Novo Nordisk obtained FDA approval for semaglutide at lower doses for T2D first (Ozempic, 2017), then developed higher-dose formulations and conducted obesity-specific clinical trials to obtain a separate obesity indication at higher doses (Wegovy, 2021).

This is common practice. The same molecule with different dose or indication approvals generates two separate commercial products, two separate regulatory filings, and — importantly — two separate insurance formulary positions.

From a Novo Nordisk commercial perspective, this allows the company to sell the T2D market as one product and the obesity market as another, with different pricing and distribution strategies.

The meaningful differences for patients

Dose difference

The maximum Ozempic dose is 2 mg/week. Wegovy goes to 2.4 mg/week via a structured dose escalation. The STEP clinical trials that established Wegovy's weight loss claims used 2.4 mg — the additional 0.4 mg above Ozempic's maximum was specifically included to maximise weight loss outcomes. Patients using Ozempic off-label for weight loss cannot access the 2.4 mg dose.

Indication difference

This matters enormously for insurance. Insurance formularies have separate categories for "diabetes medications" and "obesity/weight management medications." The same molecule is classified differently depending on which brand name you use:

• Ozempic prescribed for T2D: covered by most commercial plans, Medicare, and Medicaid as a diabetes medication
• Wegovy prescribed for obesity: covered by roughly 40–50% of commercial plans; not covered by Medicare Part D (until 2026 with the IRA provisions); coverage varies enormously by Medicaid state

This creates the well-known Ozempic-for-weight-loss situation: patients who cannot access Wegovy coverage sometimes receive Ozempic off-label for weight loss at a lower dose.

What "Ozempic off-label for weight loss" means

When a prescriber writes a prescription for Ozempic for a patient who does not have T2D, they are prescribing off-label — using an approved drug for a non-approved indication. This is legal and common in medicine.

The implications:

• Insurance will often deny coverage because the indication doesn't match (T2D drug for non-T2D patient)
• The maximum available dose is 2 mg, not 2.4 mg
• The prescriber takes responsibility for the off-label use
• The therapeutic benefit is similar to Wegovy at matched doses; the 0.4 mg difference at the top end may produce slightly different weight loss outcomes in high responders

For practical purposes, Ozempic at 1–2 mg produces meaningful weight loss in non-T2D patients — just without the FDA obesity indication and without access to the 2.4 mg dose that Wegovy offers.

Why Wegovy costs more than Ozempic

At matched doses, Wegovy is priced higher than Ozempic. At the 2 mg dose, Ozempic is approximately $960/month list price; Wegovy at 2.4 mg is approximately $1,350/month.

The pricing difference reflects:

• The obesity market positioning (premium pricing versus the T2D formulary position)
• The supply and demand dynamics (Wegovy had more demand pressure during the shortage period)
• Commercial strategy (Novo Nordisk structured two products for two markets)

This creates the counterintuitive situation where patients who can only access Ozempic (even at equivalent doses) pay less for the same molecule.

Rybelsus: semaglutide in pill form

There is a third semaglutide product worth mentioning: Rybelsus (semaglutide oral tablets, 7 mg and 14 mg daily). This is approved for T2D only, not obesity. The oral bioavailability of semaglutide is approximately 1% of the injectable form — hence much higher milligram doses are needed. It is not equivalent to Ozempic or Wegovy for weight management.

The Mounjaro/Zepbound parallel

The same situation applies to tirzepatide:

• Mounjaro: Same active molecule (tirzepatide), approved for T2D, maximum dose 15 mg/week
• Zepbound: Same active molecule (tirzepatide), approved for obesity, same maximum dose 15 mg/week

Unlike the Ozempic/Wegovy situation, Mounjaro and Zepbound share the same maximum dose — the entire difference is the FDA indication (T2D vs obesity) and therefore the insurance coverage category. For a full comparison of the two drug classes, see tirzepatide vs semaglutide.

What this means if you are choosing between Ozempic and Wegovy

If you have T2D and need both glucose and weight management: Ozempic may be the appropriate prescription (T2D indication, often better insurance coverage, lower list price).

If you do not have T2D and want maximum obesity therapy: Wegovy at 2.4 mg is the appropriate prescription (obesity indication, higher dose, but requires obesity drug insurance coverage or cash pay). Check GLP-1 eligibility criteria to confirm you meet the BMI thresholds for the obesity indication.

If you cannot get Wegovy covered but can get Ozempic covered: Off-label Ozempic for weight loss at 1–2 mg is a commonly used workaround, though maximum dose is lower. For out-of-pocket cost breakdowns, see Wegovy without insurance.

Summary

Ozempic and Wegovy are the same semaglutide molecule at different maximum doses (2 mg vs 2.4 mg) with different FDA indications (T2D vs obesity) and different insurance coverage categories. The practical consequences are: different maximum achievable dose, different insurance formulary position, and different list pricing. Patients prescribed Ozempic off-label for weight loss are using a lower maximum dose of the same drug that Wegovy represents at full therapeutic obesity dosing.